Oct. 22, 2014, 4:08 PM| Comment!
Oct. 21, 2014, 5:35 PM
- ACTG, ALB, ALGT, AWH, BCR, BDN, CA, CAKE, CLB, CLGX, CLW, CTXS, CVA, EEFT, EFX, EGHT, FTK, FTNT, GGG, IBKC, INFN, LEG, LHO, LOGI, LRCX, MKSI, MKTO, MLNX, MSA, NOW, NXPI, ORLY, OTEX, PLCM, PLXS, RE, RJF, SCSS, SFG, SGMO, SHLM, SKX, SLG, SLM, SUSQ, T, TAL, TCBI, TER, TILE, TMK, TSCO, TYL, USTR, VAR, WFT, YELP
Sep. 10, 2014, 8:06 AM
- Sangamo Biosciences (NASDAQ:SGMO) says its plans to submit an IND to the FDA for the treatment of hemophilia B based on its zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). It will be the first therapeutic application of the technology.
- The company is developing IVPRP to be a one-time permanent genetic cure for monogenic diseases. The current approach is protein replacement therapy which requires repeat infusions over the lifetime of the patient.
- Development partner Shire (NASDAQ:SHPG) Research Chief Albert Seymour, Ph.D., says, "Shire has been impressed by the rapid progress of the novel hemophilia B program developed by Sangamo. The Shire team continues to work very closely with Sangamo to submit the IND package to support this program."
- Sangamo is targeting an IND for hemophilia A by year end 2015.
Aug. 20, 2014, 5:35 PM
Jul. 23, 2014, 5:19 PM
- Sangamo BioSciences (SGMO +6.1%) Q2 results: Total Revenues: $10.4M (+49.8%), Collaboration Agreements: $9.7M (+57.9%); Operating Expenses: $17.4M (+40.6%); Net Loss: ($7.0M) (-28.1%); Quick Assets: $236.7M (+79.6%).
- 2014 Guidance: Revenues: $45M - 50M; Operating expenses: $65M - 70M; Quick Assets: at least $225M by year end.
Jul. 23, 2014, 4:10 PM| 1 Comment
Jul. 22, 2014, 5:35 PM
- AF, AHL, AIZ, ALGT, ALSN, ANGI, ANGO, AVB, AWH, BDN, CA, CAKE, CCI, CHE, CLB, CLGX, CLW, CMRE, CRUS, CSGP, CTXS, EFX, EGHT, ETFC, ETH, FB, FFIV, FLS, FR, FTNT, GGG, GILD, HBI, HWAY, IBKC, ILMN, INFN, KALU, LHO, MAC, MKSI, MSA, NSR, NVEC, NXPI, OHI, OII, ORLY, PLCM, QCOM, QTM, RE, RJF, SFG, SGMO, SKX, SLG, SLM, SUSQ, T, TAL, TCBI, TER, TEX, TILE, TMK, TQNT, TRIP, TSCO, TYL, UMPQ, USTR, VAR, WFT
May. 6, 2014, 4:29 PM
Apr. 3, 2014, 5:38 PM
Mar. 21, 2014, 7:18 AM
- Sangamo BioSciences (SGMO) prices its offering of 4,444,444 common shares at $22.50. The overallotment is 666,666 shares.
- The company expects it to close on or about March 26.
- Proceeds to fund general corporate purposes including R&D, expanding manufacturing capabilities, clinical trials and potential acquisitions.
Mar. 19, 2014, 4:39 PM
Mar. 19, 2014, 4:12 PM
Mar. 6, 2014, 12:52 PM
Mar. 6, 2014, 9:15 AM
- Gainers: PXLW +38%. BORN +30%. SGMO +17%. ERII +14%. BSPM +14%. ORAN +10%. BSDM +9%. GEVO +9%. LJPC +8%. ROX +8%. RIGL +8%. RGSE +8%. NEON +8%. PPHM +7%. NAVB +7%. FREE +6%. PSTI +6%. MVIS +5%. LOGI +5%. GRO +5%.
- Losers: LOV -20%. XGTI -13%. PLCE -12%. SPLS -11%. BLDP -8%. FCEL -6%. DANG -6%. MXWL -6%.
Mar. 6, 2014, 7:40 AM
- Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs.
- In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection. The altered cells, SB-728-T, were returned to the subjects via autologous infusion.
- The ZFN-modified cells showed preferential survival over unmodified cells and were able to persist and circulate throughout the body to key reservoirs of HIV infection such as gut-associated lymphoid tissue.
- Shares are up 14% in early trading.
Mar. 5, 2014, 6:32 PM
- Sangamo Biosciences (SGMO) +15.4% AH after announcing the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease-based genome editing technology in humans.
- SGMO says data from the study, carried out in HIV-positive subjects, shows the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection, demonstrating the feasibility of this genome editing approach to achieve functional control of HIV.
SGMO vs. ETF Alternatives
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Other News & PR